Regulation of suppressive function of myeloid-derived suppressor cells by CD4 + T cells

Seminars in Cancer Biology

Volumn 22, Issue 4, 2012, Pages 282-288

  Nagaraj, Srinivas ^b   Gabrilovich, Dmitry I ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Cancer; MDSC; T cell suppression

Indexed keywords

ARGININE; PEROXYNITRITE; REACTIVE OXYGEN METABOLITE;

AMINO ACID METABOLISM; ANTIGEN SPECIFICITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL EXPANSION; CELL INTERACTION; CELL LINEAGE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; LYMPHOCYTE FUNCTION; MOLECULAR INTERACTION; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNE TOLERANCE; MYELOID CELLS; NEOPLASMS; TUMOR ESCAPE;

EID: 84862126124     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2012.01.010     Document Type: Review

References (97)

1. Almand B., Clark J.I., Nikitina E., English N.R., Knight S.C., Carbone D.P., et al. Increased production of immature myeloid cells in cancer patients. A mechanism of immunosuppression in cancer. J Immunol 2001, 166:678-689.
2. Kusmartsev S., Li Y., Chen S-H. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol 2000, 165:779-785.
3. Pandit R., Lathers D., Beal N., Garrity T., Young M. CD34+ immune suppressive cells in the peripheral blood of patients with head and neck cancer. Ann Otol Rhinol Laryngol 2000, 109:749-754.
4. Bronte V., Serafini P., Appoloni E., Zanovello P. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunoth 2001, 24:431-446.
5. Melani C., Chiodoni C., Forni G., Colombo M.P. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003, 102:2138-2145.
6. Gabrilovich D.I. The mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004, 4:941-952.
7. Kusmartsev S., Nagaraj S., Gabrilovich D.I. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 2005, 175:4583-4592.
8. Hestdal K., Ruscetti F., Ihle J., Jacobsen S., Dubois C., Kopp W., et al. Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J Immunol 1991, 147:22-28.
9. Bronte V., Apolloni E., Cabrelle A., Ronca R., Serafini P., Zamboni P., et al. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000, 96:3838.
10. Kusmartsev S., Gabrilovich D.I. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J Leukoc Biol 2003, 74:186-196.
11. Li Q., Pan P.Y., Gu P., Xu D., Chen S.H. Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res 2004, 64:1130-1139.
12. Subiza J., Vinuela J., Rodriguez R., De la Concha E. Development of splenic natural suppressor (NS) cells in Ehrlich tumor-bearing mice. Int J Cancer 1989, 44:307-314.
13. Bronte V., Chappell D.B., Apolloni E., Cabrelle A., Wang M., Hwu P., et al. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 1999, 162:5728-5737.
14. Gabrilovich D.I., Velders M., Sotomayor E., Kast W.M. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 2001, 166:5398-5406.
15. Bronte V., Wang M., Overwijk W., Surman D., Pericle F., Rosenberg S.A., et al. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol. 1998, 161:5313-5320.
16. Cauley L., Miller E., Yen M., Swain S. Superantigen-induced CD4 T cell tolerance mediated by myeloid cells and IFN-gamma. J Immunol 2000, 165:6056.
17. Mencacci A., Montagnoli C., Bacci A., Cenci E., Pitzurra L., Spreca A., et al. CD80+Gr-1+ myeloid cells inhibit development of antifungal Th1 immunity in mice with candidiasis. J Immunol 2002, 169:3180-3190.
18. Atochina O., Daly-Angel T., Piskorska D., Harn D. A shistosome expressed immunomodulatory glycoconjugate expand peritoneal Gr1+ macrophages that suppress naïve CD4+ T cell proliferation via an interferon-gamma and nitric oxide dependent mechanism. J Immunol 2001, 167:4293-4302.
19. Dietlin T.A., Hofman F.M., Lund B.T., Gilmore W., Stohlman S.A., van der Veen R.C. Mycobacteria-induced Gr-1+ subsets from distinct myeloid lineages have opposite effects on T cell expansion. J Leukoc Biol 2007, 81:1205-1212.
20. Zhu B., Bando Y., Xiao S., Yang K., Anderson A.C., Kuchroo V.K., et al. CD11b+Ly-6Chi suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol 2007, 179:5228-5237.
21. Dolcetti L., Peranzoni E., Ugel S., Marigo I., Fernandez Gomez A., Mesa C., et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 2010, 40:22-35.
22. Movahedi K., Guilliams M., Van den Bossche J., Van den Bergh R., Gysemans C., Beschin A., et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008, 111:4233-4244.
23. Youn J.I., Nagaraj S., Collazo M., Gabrilovich D.I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008, 181:5791-5802.
24. Van Ginderachter J.A., Meerschaut S., Liu Y., Brys L., De Groeve K., Hassanzadeh Ghassabeh G., et al. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood 2006, 108:525-535.
25. Bronte V., Apolloni E., Cabrelle A., Ronca R., Serafini A., Zamboni P., et al. Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+ T cells. Blood 2000, 96:3838-3846.
26. Sica A., Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007, 117:1155-1166.
27. Youn J.-I., Collazo M., Shalova I., Biswas S., Gabrilovich D. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol 2012, 91:167-181.
28. Brandau S., Trellakis S., Bruderek K., Schmaltz D., Steller G., Elian M., et al. Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol 2011, 89:311-317.
29. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23:549-555.
30. Rodriguez P.C., Quiceno D.G., Ochoa A.C. l-Arginine availability regulates T-lymphocyte cell-cycle progression. Blood 2007, 109:1568-1573.
31. Rodriguez P.C., Hernandez C.P., Quiceno D., Dubinett S.M., Zabaleta J., Ochoa J.B., et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 2005, 202:931-939.
32. Rodriguez P.C., Zea A.H., Culotta K.S., Zabaleta J., Ochoa J.B., Ochoa A.C. Regulation of T cell receptor CD3zeta chain expression by l-arginine. J Biol Chem 2002, 277:21123-21129.
33. Liu Y., Van Ginderachter J., Brys L., De Baetselier P., Raes G., Geldhof A. Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells. J Immunol 2003, 170:5064-5074.
34. Bronte V., Serafini P., De Santo C., Marigo I., Tosello V., Mazzoni A., et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol 2003, 170:270-278.
35. Rodriguez P.C., Quiceno D.G., Zabaleta J., Ortiz B., Zea A.H., Piazuelo M.B., et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004, 64:5839-5849.
36. Kusmartsev S., Gabrilovich D. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol 2005, 174:4880-4891.
37. Bronte V., Casic T., Gri G., Gallana K., Borsellino G., Marrigo I., et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 2005, 201:1257-1268.
38. Zea A.H., Rodriguez P.C., Atkins M.B., Hernandez C., Signoretti S., Zabaleta J., et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005, 65:3044-3048.
39. Kusmartsev S., Nefedova Y., Yoder D., Gabrilovich D.I. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004, 172:989-999.
40. Otsuji M., Kimura Y., Aoe T., Okamoto Y., Saito T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci U S A 1996, 93:13119-13124.
41. Schmielau J., Finn O.J. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 2001, 61:4756-4760.
42. Szuster-Ciesielska A., Hryciuk-Umer E., Stepulak A., Kupisz K., Kandefer-Szerszen M. Reactive oxygen species production by blood neutrophils of patients with laryngeal carcinoma and antioxidative enzyme activity in their blood. Acta Oncol 2004, 43:252-258.
43. Sauer H., Wartenberg M., Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem 2001, 11:173-186.
44. Waris G., Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog 2006, 5:14.
45. Mantovani G., Maccio A., Madeddu C., Mura L., Gramignano G., Lusso M.R., et al. Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. J Mol Med 2003, 81:664-673.
46. Agostinelli E., Seiler N. Non-irradiation-derived reactive oxygen species (ROS) and cancer: therapeutic implications. Amino Acids 2006, 31:341-355.
47. Bingisser R.M., Tilbrook P.A., Holt P.G., Kees U.R. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol 1998, 160:5729-5734.
48. Harari O., Liao J.K. Inhibition of MHC II gene transcription by nitric oxide and antioxidants. Curr Pharm Des 2004, 10:893-898.
49. Rivoltini L., Carrabba M., Huber V., Castelli C., Novellino L., Dalerba P., et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 2002, 188:97-113.
50. Nagaraj S., Gupta K., Pisarev V., Kinarsky L., Sherman S., Kang L., et al. Altered recognition of antigen is a novel mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007, 13:828-835.
51. Lu T., Ramakrishnan R., Altiok S., Youn J.I., Cheng P., Celis E., et al. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest 2011, 121:4015-4029.
52. Molon B., Ugel S., Del Pozzo F., Soldani C., Zilio S., Avella D., et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med. 2011.
53. Pan P.Y., Ma G., Weber K.J., Ozao-Choy J., Wang G., Yin B., et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010, 70:99-108.
54. Huang B., Pan P.Y., Li Q., Sato A.I., Levy D.E., Bromberg J., et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006, 66:1123-1131.
55. Serafini P., Mgebroff S., Noonan K., Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008, 68:5439-5449.
56. Sakuishi K., Jayaraman P., Behar S.M., Anderson A.C., Kuchroo V.K. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol 2011, 32:345-349.
57. Hanson E.M., Clements V.K., Sinha P., Ilkovitch D., Ostrand-Rosenberg S. Myeloid-derived suppressor cells down-regulate l-selectin expression on CD4+ and CD8+ T cells. J Immunol 2009, 183:937-944.
58. Young M.R.I., Wright M.A., Matthews J.P., Malik I., Pandit R. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-b and nitric oxide. J Immunol 1996, 156:1916-1921.
59. Beck C., Schreiber K., Schreiber H., Rowley D. C-kit+ FcR+ myelocytes are increased in cancer and prevent the proliferation of fully cytolytic T cells in the presence of immune serum. Eur J Immunol 2001, 33:19-28.
60. Terabe M., Matsui S., Park J.M., Mamura M., Noben-Trauth N., Donaldson D.D., et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003, 198:1741-1752.
61. Srivastava M.K., Sinha P., Clements V.K., Rodriguez P., Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 2010, 70:68-77.
62. Bunt S.K., Clements V.K., Hanson E.M., Sinha P., Ostrand-Rosenberg S. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J Leukoc Biol 2009, 85:996-1004.
63. Yang R., Cai Z., Zhang Y., Ht Yutzy W., Roby K.F., Roden R.B. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res 2006, 66:6807-6815.
64. Blank C., Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007, 56:739-745.
65. Collins M., Ling V., Carreno B.M. The B7 family of immune-regulatory ligands. Genome Biol 2005, 6:223.
66. Nagaraj S., Gupta K., Pisarev V., Kinarsky L., Sherman S., Kang L., et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007, 13:828-835.
67. Nagaraj S., Schrum A.G., Cho H.I., Celis E., Gabrilovich D.I. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol 2010, 184:3106-3116.
68. Solito S., Bronte V., Mandruzzato S. Antigen specificity of immune suppression by myeloid-derived suppressor cells. J Leukoc Biol 2011, 90:31-36.
69. Chalmin F., Ladoire S., Mignot G., Vincent J., Bruchard M., Remy-Martin J.P., et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 2010, 120:457-471.
70. Kodumudi K.N., Woan K., Gilvary D.L., Sahakian E., Wei S., Djeu J.Y. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 2010, 16:4583-4594.
71. Sinha P., Clements V., Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 2005, 174:636-645.
72. Rodriguez P.C., Ernstoff M.S., Hernandez C., Atkins M., Zabaleta J., Sierra R., et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009, 69:1553-1560.
73. Vuk-Pavlovic S., Bulur P.A., Lin Y., Qin R., Szumlanski C.L., Zhao X., et al. Immunosuppressive CD14+HLA-DRlow/-monocytes in prostate cancer. Prostate 2010, 70:443-455.
74. Nagaraj S, Nelson A, Youn J, Cheng P, Quiceno D, Gabrilovich D. Antigen-specific CD4+ T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC class II signaling. Cancer Res 2012; in press.
75. Nefedova Y., Huang M., Kusmartsev S., Bhattacharya R., Cheng P., Salup R., et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol 2004, 172:464-474.
76. Wang T., Niu G., Kortylewski M., Burdelya L., Shain K., Zhang S., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004, 10:48-54.
77. Kortylewski M., Kujawski M., Wang T., Wei S., Zhang S., Pilon-Thomas S., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005, 11:1314-1321.
78. Chan L.L., Cheung B.K., Li J.C., Lau A.S. A role for STAT3 and cathepsin S in IL-10 down-regulation of IFN-gamma-induced MHC class II molecule on primary human blood macrophages. J Leukoc Biol 2010, 88:303-311.
79. Kitamura H., Kamon H., Sawa S., Park S.J., Katunuma N., Ishihara K., et al. IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells. Immunity 2005, 23:491-502.
80. Nefedova Y., Cheng P., Gilkes D., Blaskovich M., Beg A.A., Sebti S.M., et al. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol 2005, 175:4338-4346.
81. Poschke I., Mougiakakos D., Hansson J., Masucci G.V., Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010, 70:4335-4345.
82. Filipazzi P., Valenti R., Huber V., Pilla L., Canese P., Iero M., et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007, 25:2546-2553.
83. Solito S., Falisi E., Diaz-Montero C.M., Doni A., Pinton L., Rosato A., et al. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 2011.
84. Xiang X., Poliakov A., Liu C., Liu Y., Deng Z.B., Wang J., et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer 2009, 124:2621-2633.
85. Donkor M.K., Lahue E., Hoke T.A., Shafer L.R., Coskun U., Solheim J.C., et al. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. Int Immunopharmacol 2009, 9:937-948.
86. Harizi H., Juzan M., Pitard V., Moreau J., Gualde N. Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J Immunol 2002, 68:2255-2263.
87. Sinha P., Clements V.K., Fulton A.M., Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007, 67:4507-4513.
88. Liang B., Workman C., Lee J., Chew C., Dale B.M., Colonna L., et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 2008, 180:5916-5926.
89. Al-Daccak R., Mooney N., Charron D. MHC class II signaling in antigen-presenting cells. Curr Opin Immunol 2004, 16:108-113.
90. Kissner T.L., Ruthel G., Alam S., Ulrich R.G., Fernandez S., Saikh K.U. Activation of MyD88 signaling upon staphylococcal enterotoxin binding to MHC class II molecules. PLoS ONE 2011, 6:e15985.
91. Wang S., Liu Z., Wang L., Zhang X. NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell. Mol. Immunol. 2009, 6:327-334.
92. Frei R., Steinle J., Birchler T., Loeliger S., Roduit C., Steinhoff D., et al. MHC class II molecules enhance Toll-like receptor mediated innate immune responses. PLoS ONE 2010, 5:e8808.
93. Liu X., Zhan Z., Li D., Xu L., Ma F., Zhang P., et al. Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol 2011, 12:416-424.
94. Milkiewicz M., Uchida C., Gee E., Fudalewski T., Haas T.L. Shear stress-induced Ets-1 modulates protease inhibitor expression in microvascular endothelial cells. J Cell Physiol 2008, 217:502-510.
95. Schunke D., Span P., Ronneburg H., Dittmer A., Vetter M., Holzhausen H.J., et al. Cyclooxygenase-2 is a target gene of rho GDP dissociation inhibitor beta in breast cancer cells. Cancer Res 2007, 67:10694-10702.
96. Zhang X., Zhang J., Yang X., Han X. Several transcription factors regulate COX-2 gene expression in pancreatic beta-cells. Mol Biol Rep 2007, 34:199-206.
97. Tanabe T., Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prost Other Lipid Mediat 2002, 68-69:95-114.